In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with a price target of $17.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Naz Rahman has given his Buy rating due to a combination of factors, primarily focusing on Nuvectis Pharma’s lead asset, NXP900. The company has shifted its attention entirely to NXP900 following less favorable outcomes from another asset, NXP800. NXP900 is being developed to address a significant need in the treatment of non-small cell lung cancer, particularly for patients who have developed resistance to existing EGFR and ALK inhibitors. The upcoming Phase 1b study, which is set to begin shortly, is a critical step in advancing this promising therapy.
NXP900 has demonstrated potential in resensitizing cancer cells to antitumor treatments, which is a crucial development for patients with limited options. The study will include different patient cohorts, including those previously treated with EGFR and ALK inhibitors, to assess the drug’s efficacy in combination therapies. The financial position of Nuvectis, bolstered by recent funding, provides a runway into the second half of 2027, supporting the continued development of NXP900. These factors collectively underpin Rahman’s positive outlook and Buy rating for Nuvectis Pharma.
Rahman covers the Healthcare sector, focusing on stocks such as Nuvectis Pharma, Kazia Therapeutics, and Aytu BioScience. According to TipRanks, Rahman has an average return of -16.6% and a 30.94% success rate on recommended stocks.
In another report released on August 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.